Hospital
NPI deactivated
Northeast Montana Health Services, INC.
Northeast Montana Health Services, INC. was paid $1.04M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is A0429, emergency ambulance ride, basic life support — 66% of everything it billed.
33Billing provider infoNORTHEAST MONTANA HEALTH SERVICES, INC.
POPLAR, MT 59255
POPLAR, MT 59255
33aNPI1396766903assigned 07/21/2006
33bProvider typeCritical Access Hospital
28Total paid$1.04M
24GClaims99,155
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Montana
Rank by total paid#4 of 25
Median peer was paid$185K
This provider vs. median5.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,347 | $152K | |
| 2019 | 13,680 | $153K | |
| 2020 | 12,750 | $184K | |
| 2021 | 14,687 | $139K | |
| 2022 | 17,004 | $160K | |
| 2023 | 16,556 | $148K | |
| 2024incomplete | 10,131 | $102K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 66% | 3,731 | 2,960 | $686K |
| A0380 | Bls mileage (per mile) | 5.7% | 1,827 | 1,516 | $59K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 5,918 | 5,443 | $48K |
| A0382 | Bls routine disposable supplies | 4.5% | 1,034 | 973 | $47K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.7% | 3,411 | 3,152 | $28K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.5% | 117 | 107 | $26K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 2,387 | 2,153 | $19K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 1,023 | 969 | $18K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.0% | 2,092 | 1,901 | $11K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 1,212 | 1,074 | $9K |
| 80053 | Comprehensive metabolic panel | <1% | 7,375 | 6,074 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,036 | 969 | $8K |
85 more codes
| 76376 | <1% | 1,056 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,917 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,775 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,171 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,663 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 802 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,301 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,663 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,210 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,567 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,398 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,202 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,486 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,951 | $2K |
| 80305 | <1% | 3,368 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 533 | $1K |
| 87634 | <1% | 539 | $1K | |
| 81001 | <1% | 4,133 | $1K | |
| 96376 | <1% | 275 | $1K | |
| 87631 | <1% | 43 | $837.00 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,924 | $692.99 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 671 | $668.45 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,207 | $571.61 |
| 86780 | <1% | 1,234 | $499.72 | |
| 85027 | <1% | 514 | $427.92 | |
| 84484 | <1% | 1,153 | $403.19 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 965 | $399.17 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 966 | $389.65 |
| 80074 | <1% | 435 | $360.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 297 | $331.72 |
| 81025 | <1% | 406 | $329.86 | |
| 96367 | <1% | 83 | $247.50 | |
| 73610 | <1% | 14 | $222.97 | |
| 71045 | Radiologic examination, chest; single view | <1% | 349 | $190.80 |
| 83605 | <1% | 668 | $187.87 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 899 | $187.18 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 547 | $172.57 |
| 85610 | <1% | 1,316 | $158.96 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 84 | $152.85 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 509 | $149.34 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 56 | $135.00 |
| 82077 | <1% | 367 | $113.84 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 126 | $99.00 |
| 83690 | <1% | 1,024 | $96.75 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 91 | $89.32 |
| 86140 | <1% | 28 | $75.60 | |
| 83735 | <1% | 43 | $75.59 | |
| 84703 | <1% | 130 | $70.64 | |
| 85652 | <1% | 26 | $48.39 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $32.44 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 173 | $32.40 |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 59 | $0.00 |
| 86900 | 0% | 65 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 929 | $0.00 |
| 82805 | 0% | 28 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 186 | $0.00 |
| 84145 | 0% | 95 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| 73130 | 0% | 16 | $0.00 | |
| 71250 | 0% | 16 | $0.00 | |
| 36600 | 0% | 15 | $0.00 | |
| 74018 | 0% | 14 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 14 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 39 | $0.00 |
| 86762 | 0% | 90 | $0.00 | |
| 85730 | 0% | 27 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 114 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 29 | $0.00 |
| 70486 | 0% | 131 | $0.00 | |
| 86803 | 0% | 94 | $0.00 | |
| 80320 | 0% | 28 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 174 | $0.00 |
| 86901 | 0% | 65 | $0.00 | |
| G0378 | Hospital observation service, per hour | 0% | 44 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 43 | $0.00 |
| 86850 | 0% | 35 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 42 | $0.00 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 17 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 14 | $0.00 |
| 82150 | 0% | 14 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 14 | $0.00 |
| 83880 | 0% | 35 | $0.00 | |
| 94680 | 0% | 15 | $0.00 | |
| 85379 | 0% | 16 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBALAND, RICHARD (CFO)
| Provider | Location | Paid |
|---|---|---|
| North Sonoma County Health Care District | Healdsburg, CA | $5.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.